Novartis to present novel data from its immunology portfolio at international congresses | The Financial Express

Novartis to present novel data from its immunology portfolio at international congresses

The pharma major claim that Novartis’s ambition is to reduce the suffering from immunological conditions, which affect up to 4.5 percent of the world’s population and can have a significant impact on quality of life.

Novartis to present novel data from its immunology portfolio at international congresses
During the conference, targets to address the global antimicrobial resistance (AMR) challenge were discussed for the first time. (File)

Novartis on Friday announced it will showcase data from its leading immunology portfolio and emerging pipeline at the upcoming 31st European Academy of Dermatology and Venereology (EADV) Congress and the 15th International Symposium on Sjögren’s Syndrome (ISSS), both occurring from September 7 to September 10, 2022.

According to the company’s press statement, a total of 37 abstracts will be shared across both meetings, spanning hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU), Sjögren’s syndrome, axial spondyloarthritis, and psoriasis.

“These data – including late-breaking results from our pivotal trials for Cosentyx in hidradenitis suppurativa – demonstrate both the strength of our portfolio, and our commitment to pioneering the medicines of tomorrow in immunology. We are focusing our development efforts on immunological diseases with significant unmet need, and hope that we will soon be able to provide more treatment options to patients to manage their conditions,” said Angelika Jahreis M.D., Ph.D., FAAD, Global Head Development Unit Immunology and Clinical Development Excellence, Novartis in a statement on Friday.

ALSO READ | Novartis appoints Fiona Marshall as President of Novartis Institutes for Biomedical Research

The pharma major claim that Novartis’s ambition is to reduce the suffering from immunological conditions, which affect up to 4.5 percent of the world’s population and can have a significant impact on quality of life.

Moreover, the company is reportedly exploring potential biologic and oral treatments with various mechanisms of action in HS, developing medicines that could help those living with CSU achieve complete symptom control, and advancing research in Sjögren’s syndrome, for which there are currently no disease-modifying treatments available.

“To assess and elevate the patient perspective at every stage of its clinical research, Novartis will also share the latest findings from a number of patient-based initiatives at EADV, including the global Psoriasis and Beyond study exploring the impact of psoriatic disease on mental health. Results from a comprehensive social media monitoring program to help illuminate the significant unmet needs of people living with HS will also be presented,” the company said in a press statement on Friday.

Along with trial results of Cosentyx, Novartis will also present data on Remibrutinib (LOU064) and a few patient studies.

ALSO READ | Novartis announces intention to separate Sandoz business to create standalone company

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.

Photos
7 Photos
Assembly Election Results 2022: BJP’s celebratory dance in Gujarat, Congress exudes confidence in Himachal – See Photos
10 Photos
Realme 10 Pro Plus launched in India: The 10-point rough cut
9 Photos
AAP sweeps away 15 year BJP reign in MCD election – Photos from celebrations